Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

L.A. McKeown

November 11, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Daily News

Worse Complications After PVI in Women Highlight Research Gaps

L.A. McKeown

August 16, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Caitlin E. Cox

January 10, 2019

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

L.A. McKeown

December 07, 2018

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

L.A. McKeown

November 06, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

Shelley Wood

October 02, 2018

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

Todd Neale

September 24, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

News Daily News

Same-Day Discharge After Peripheral Interventions Gets Mixed Results in Pilot Study

Todd Neale

March 22, 2018

News Conference News ISET 2018

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

Caitlin E. Cox

February 13, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

L.A. McKeown

May 03, 2017

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

L.A. McKeown

September 21, 2016

Advertisement

Top Endovascular News of 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

FDA Approves Bioresorbable Scaffold for BTK Lesions

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

Worse Complications After PVI in Women Highlight Research Gaps

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

TCTMD’s Top 10 Most Popular Stories for September 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Same-Day Discharge After Peripheral Interventions Gets Mixed Results in Pilot Study

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content